Acute promyelocytic leukemia as a model for cross-talk between interferon and retinoic acid pathways: From molecular biology to clinical applications

Leukemia and Lymphoma

Volumn 30, Issue 1-2, 1998, Pages 11-22

  Gaboli, Mirella ^a   Gandini, Domenica ^a   Delva, Laurent ^a   Wang, Zhu Gang ^a   Pandolfi, Pier Paolo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute promyelocytic leukemia; Interferons; IRF 1; P21(WAF1 CIP1); PML; PML RAR ; Retinoic acid; STAT 1

Indexed keywords

CELL NUCLEUS RECEPTOR; CYTOKINE; INTERFERON; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; DISEASE MODEL; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA CELL LINE; LEUKEMIA REMISSION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; RELAPSE; REVIEW;

EID: 0031815756     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809050925     Document Type: Review

References (119)

1. Bennet, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R. and Sultan, C. (1976). Proposal for the classification of the acute leukemias. Br. J. Haematol., 33, 451-458.
2. Groopman, J. and Ellman, L. (1979). Acute promyelocytic leukemia. Am. J. Hematol., 7, 395-408.
3. Stone, R. M. and Mayer, R. J. (1990). The unique aspects of acute promyelocytic leukaemia. J. Clin. Oncol., 8, 1913-1910.
4. Borrow, J., Goddard, A. D., Sheer, D. and Solomon, E. (1990). Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science, 249, 1577-1580.
5. de Thé, H., Chomienne, C., Lanotte, M., Degos, L. and Dejean, A. (1990). The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature, 347, 558-561.
6. Longo, L., Pandolfi, P. P., Biondi, A., Rambaldi, A., Mencarelli, A., Lo Coco, F., Diverio, D., Pegoraro, L., Avanzi, G., Tabilio, A., Zangrilli, D., Alcalay, M., Donti, E., Grignani, F. and Pelicci, P. G. (1990). Rearrangements and aberrant expression of the RARα gene in acute promyelocytic leukemias. J. Exp. Med., 172, 1571-1575.
7. Alcalay, M., Zangrilli, D., Pandolfi, P. P., Longo, L., Mencarelli, A., Giacomucci, A., Rocchi, M., Biondi, A., Rambaldi, A., Lo Coco, F., Diverio, D., Donti, E., Grignani, F. and Pelicci, P. G. (1991). Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc. Natl. Acad. Sci. USA, 172, 1977-1981.
8. Pandolfi, P. P., Grignani, F., Alcalay, M., Mencarelli, A., Biondi, A., Lo Coco, F. and Pelicci, P. G. (1991). Structure and origin of the acute promyelocytic leukemia myl/RARα cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene, 6, 1285-1292.
9. de Thé, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L. and Dejean, A. (1991). The PML/RARα fusion mRNA generated by the 1(15;17) translocation in acute promyelocytic leukaemia encodes a functionally altered RAR. Cell, 66, 675-684.
10. Kakizuka, A., Miller, W. H., Jr., Umesono, K., Warrell, R. P., Jr., Frankel, S. R., Murty, V. V. V. S., Dmitrovsky, E. and Evans, R. M. (1991). Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell, 66, 663-674.
11. Grignani, F., Fagioli, M., Alcalay, M., Longo, L., Pandolfi, P. P., Donti, E., Biondi, A., Lo Coco, F. and Pelicci, P. G. (1994). Acute promyelocytic leukemia: from genetics to treatment. Blood, 83, 10-25.
12. Huang, M. E., Yu-Chen, Y., Shu-Rong, C., Chai, J., Lin, Z., Long, J. and Wang, Z. (1988). Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72, 567-560.
13. Degos, L., Chomienne, C., Daniel, M. T., Berger, R., Dombret, H., Fenaux, P. and Castaigne, S. (1990). Treatment of first relapse in acute promyelocytic leukemia with all-trans retinoic acid. Lancet, 336, 1440-1441.
14. Warrell, R. P., Jr., de Thé, H., Wang, Z. Y. and Degos, L. (1993). Acute promyelocytic leukemia. N. Engl. J. Med., 329, 177-189.
15. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995). The nuclear receptor superfamily: the second decade. Cell, 83, 835-9.
16. Wang, Z. G., Delva, L., Gaboli, M., Zhang, H., Rivi, R., Cordon-Cardo, C., Grosveld, F. and Pandolfi, P. P. (1997). Targeted disruption of the PML gene results in tumor susceptibility. (Submitted).
17. Pandolfi, P. P., Alcalay, M., Fagioli, M., Zangrilli, D., Mencarelli, A., Diverio, D., Biondi, A., Lo Coco, F., Rambaldi, A., Grignani, F., Rochette-Egly, C., Gaub, M.-P., Chambon, P. and Pelicci, P. G. (1992). Genomic variability and alternative splicings generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML/RARα isoforms in acute promyelocytic leukemias. EMBO J., 11, 1397-1407.
18. Stadler, M., Chelbi-Alix, M. K., Koken, M. H., Venturini, L., Lee, C., Saib, A., Quignon, F., Pelicano, L., Guillemin, M. C., Schindler, C. et al. (1995). Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene, 11, 2565-73.
19. Lavau, C., Marchio, A., Fagioli, M., Jansen, J., Falini, B., Lebon, P., Grosveld, F., Pandolfi, P. P., Pelicci, P. G. and Dejean, A. (1995). The PML gene is a primary target for interferon. Oncogene, 11, 871-876.
20. Chelbi-Alix, M. K., Pelicano, L., Quignon, F., Koken, M. H., Venturini, L., Stadler, M., Pavlovic, J., Degos, L. and de Thé, H. (1995). Induction of the PML protein by interferons in normal and APL cells. Leukemia, 9, 2027-33.
21. Nason-Burchenal, K., Gandini, D., Botto, M., Allopenna, J., Scale, J. R. C. Cross, N. C. P., Goldman, J. M., Dmitrovsky, E. and Pandolfi, P. P. (1996). Interteron augments PML and PML/RARα expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans-retinoic acid to induce maturation of a retinoid resistant promyelocytic cell line. Blood, 889, 3926-3936.
22. Kumar, R. and Korutla, L. (1995). Growth inhibition of human acute promyelocytic leukemia NB-4 cells by interferons and all-trans retinoic acid: trans-modulation of inducible gene expression pathways. Anticancer Res., 15, 353-60.
23. Matikainen, S., Ronni, T., Lehtonen, A., Sareneva, T., Melen, K., Nordling, S., Levy, D. E. and Julkunen, I. (1997). Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell. Growth Differ., 8, 687-98.
24. Trinchieri, G., Rosen, M. and Perussia, B. (1987). Retinoic acid cooperates with tumor necrosis factor and immune interferon in inducing differentiation and growth inhibition of the human promyelocytic leukemic cell line HL-60. Blood, 69, 1218-24.
25. Hemmi, H. and Breitman, T. R. (1987). Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood, 69, 501-7.
26. Ho, C. K. (1985). Synergistic anticellular effect of a combination of beta-interferon and retinoic acid against U937 cells. Cancer Res., 45, 5348-51.
27. Kohlhepp, E. A., Condon, M. E. and Hamburger, A. W. (1987). Recombinant human interferon alpha enhancement of retinoic-acid-induced differentiation of HL-60 cells. Exp. Hematol, 15, 414-8.
28. Mutikainen, S., Ronni, T., Hurme, M., Pine, R. and Julkunen, I. (1996). Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood, 88, 114-23.
29. Gianni, M., Terao, M., Fortino, I., LiCalzi, M., Viggiano, V., Barbui, T., Rambaldi, A. and Garattini, E. (1997). Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood, 89, 1001-12.
30. Liu, M., Iavarone, A. and Freedman, L. P. (1996). Transcriptional activation of the human p21 (WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J. Biol. Chem., 271, 31723-8.
31. Chin, Y. E., Kitagawa, M., Su, W. C., You, Z. H., Iwamoto, Y. and Fu, X. Y. (1996). Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science, 272, 719-22.
32. Landolfo, S., Gribaudo, G., Angeretti, A. and Gariglio, M. (1995). Mechanisms of viral inhibition by interferons. Pharmacol. Ther., 65, 415-42.
33. David, M. (1995). Transcription factors in interferon signaling. Pharmacol. Ther., 65, 149-61.
34. Staeheli, P. (1990). Interferon-induced proteins and the antiviral state. Adv. Virus Res., 38, 147-200.
35. Lengyel, P. (1993). Tumor-suppressor genes: news about the interferon connection. Proc. Natl. Acad. Sci. U S A, 90, 5893-5.
36. Gutterman, J. U. (1994). Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. U S A, 91, 1198-205.
37. Sen, G. C. and Lengyel, P. (1992). The interferon system. A bird's eye view of its biochemistry. J. Biol. Chem., 267, 5017-20.
38. Darnell, J. E., Jr., Kerr, I. M. and Stark, G. R. (1994). Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264, 1415-21.
39. Schindler, C. and Darnell, J. E., Jr. (1995). Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem., 64, 621-51.
40. Ihle, J. N. (1996). STATs: signal transducers and activators of transcription. Cell. 84, 331-4.
41. Ihle, J. N., Witthuhn, B. A., Quelle, F. W., Yamamoto, K., Thierfelder, W. E., Kreider, B. and Silvennoinen, O. (1994). Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem. Sci., 19, 222-7.
42. Ziemiecki, A., Harpur, A. G. and Wilks, A. F. (1994). JAK protein tyrosine kinase: their role in cytokine signalling. Trends in Cell Biol., 4, 207-212.
43. Lew, D. J., Decker, T., Strehlow, I. and Darnell, J. E. (1991). Overlapping elements in the guanylate-binding protein gene promoter mediate transcriptional induction by alpha and gamma interferons. Mol. Cell. Biol., 11, 182-91.
44. Chambon, P. (1994). The retinoid signaling pathway: molecular and genetic analyses. Semin. Cell Biol., 5, 115-25.
45. Mangelsdorf, D. J. and Evans, R. M. (1995). The RXR heterodimers and orphan receptors. Cell, 83, 841-50.
46. Leid, M., Kastner, P. and Chambon, P. (1992). Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem. Sci., 17, 427-33.
47. Chambon, P. (1996). A decade of molecular biology of retinoic acid receptors. FASEB J., 10, 940-54.
48. Glass, C. K., Rose, D. W. and Rosenfeld, M. G. (1997). Nuclear receptor coactivators. Curr. Opin. Cell Biol., 9, 222-32.
49. de Thé, H., Marchio, A., Tiollais, P. and Dejean, A. (1989). Differential expression and ligand regulation of the retinoic acid receptor α and β genes. EMBO J, 8, 429-433.
50. Collins, S. J., Robertson, K. and Mueller, L. (1990). Retinoic acid induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-α). Mol. Cell. Biol., 10, 2154-2163.
51. Chomienne, C. Balitrand, N., Ballerini, P., Castaigne, S., de Thé, H. and Degos, L. (1991). All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. J. Clin. Invest., 88, 2150-4.
52. Robertson, K. A., Emami, B., Mueller, L. and Collins, S. J. (1992). Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. Mol. Cell. Biol., 12, 3743-3749.
53. Tsai, S., Bartelmez, S., Heyman, R., Damm, K., Evans, R. M. and Collins, S. J. (1992). A mutated retinoic acid receptor-α exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line. Genes Dev., 6, 2258-2269.
54. Vasios, G. W., Gold, J. D., Petkovich, M., Chambon, P. and Gudas, L. J. (1989). A retinoic acid-responsive element is present in the 5′ flanking region of the laminin B1 gene. Proc. Natl Acad. Sci. U S A, 86, 9099-103.
55. Smith, M. A., Parkinson, D. R., Cheson, B. D. and Friedman, M. A. (1992). Retinoids in cancer therapy. J. Clin. Oncol., 10, 839-864.
56. Gudas, L. J. (1994). Retinoids and vertebrate development. J. Biol. Chem., 269, 15399-402.
57. Froeschlé, A., Carnac, G., Alric, S., Montarras, D., Pinset, C., Rochette-Egly, C. and Bonnieu, A. (1996). RXR alpha is essential for mediating the all-trans retinoic acid-induced growth arrest of C2 myogenic cells. Oncogene, 12, 411-21.
58. Pomponi, F., Cariati, R., Zancai, P., De Paoli, P., Rizzo, S., Tedeschi, R. M., Pivetta, B., De Vita, S., Boiocchi, M. and Dolcetti, R. (1996). Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood, 88, 3147-59.
59. Ahn, M. J., Nason-Burchenal, K., Moasser, M. and Dmitrovsky, E. (1995). Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RARα or PML. Oncogene, 10, 2307-2300.
60. Schule, R., Rangarajan, P., Yang, N., Kliewer, S., Ransone, L. J., Bolado, J., Verma, I. M. and Evans, R. M. (1991). Retinoic acid is a negative regulator of AP-1-responsive genes. Proc. Natl. Acad. Sci. U S A, 88, 6092-6.
61. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S. C., Heyman, R. A., Rose, D. W., Glass, C. K. and Rosenfeld, M.G. (1996). A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell, 85, 403-14.
62. Lippman, S. M., Glisson, B. S., Kavanagh, J. J., Lotan, R., Hong, W. K., Paredes-Espinoza, M., Hittelman, W. N., Holdener, E. E. and Krakoff, I. H. (1993). Retinoic acid and Interferon combination studies in human cancer. Eur. J. Cancer., 29A Suppl 5, S9-13.
63. Moore, D. M., Kalvakolanu, D. V., Lippman, S. M., Kavanagh, J. J., Hong, W. K., Borden, E. C., Paredes-Espinoza, M. and Krakoff, I. H. (1994). Retinoic acid and Interferon in human cancer: mechanistic and clinical studies. Semin. Hematol., 31, 31-7.
64. Lippman, S. M., Lotan, R. and Schleuniger, U. (1997). Retinoid-interferon therapy of solid tumors. Int. J. Cancer, 70, 481-3.
65. Lancillotti, F., Giandomenico, V., Affabris, E., Fiorucci, G., Romeo, G. and Rossi, G. B. (1995). Interferon alpha-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells. Cancer Res., 55, 3158-64.
66. Giandomenico, V., Lancillotti, F., Fiorucci, G., Percario, Z. A., Rivabene, R., Malorni, W., Affabris, E. and Romeo, G. (1997). Retinoic acid and IFN inhibition of cell proliferation is associated with apoptosis in squamous carcinoma cell lines: role of IRF-1 and TGase II-dependent pathways. Cell Growth Differ., 8, 91-100.
67. Weihua, X., Kolla, V. and Kalvakolanu, D. V. (1997). Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J. Biol. Chem., 272, 9742-8.
68. Kolla, V., Lindner, D. J., Xiao, W., Borden, E. C. and Kalvakolanu, D. V. (1996). Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J. Biol. Chem., 271, 10508-14.
69. Harada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M., Furia, A., Miyata, T. and Taniguchi, T. (1989). Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell, 58, 729-39.
70. Matsuyama, T., Kimura, T., Kitagawa, M., Pfeffer, K., Kawakami, T., Watanabe, N., Kundig, T. M., Amakawa, R., Kishihara, K., Wakeham, A., et al. (1993). Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell, 75, 83-97.
71. Tanaka, N., Ishihara, M., Kitagawa, M., Harada, H., Kimura, T., Matsuyama, T., Lamphier, M. S., Aizawa, S., Mak, T. W. and Taniguchi, T. (1994). Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell, 77, 829-39.
72. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-4.
73. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin- dependent kinases. Cell, 75, 805-16.
74. Gu, Y., Turck, C. W. and Morgan, D. O. (1993). Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature, 366, 707-10.
75. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-25.
76. Kano, A., Watanabe, Y., Takeda, N., Aizawa, S. and Akaike, T. (1997). Analysis of IFN-gamma-induced cell cycle arrest and cell death in hepatocytes. J. Biochem. (Tokyo), 121, 677-83.
77. Hobeika, A. C., Subramaniam, P. S. and Johnson, H. M. (1997). IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene, 14, 1165-70.
78. Sangfelt, O., Erickson, S., Einhorn, S. and Grander, D. (1997). Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines. Oncogene, 14, 415-23.
79. Subramaniam, P. S. and Johnson, H. M. (1997). A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons. J. Interferon Cytokine Res., 17, 11-5.
80. Biggs, J. R., Kudlow, J. E. and Kraft, A. S. (1996). The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J. Biol. Chem., 271, 901-6.
81. Jiang, H., Lin, J., Su, Z. Z., Collart, F. R., Huberman, E. and Fisher, P. B. (1994). Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/ CIP1, expression in the absence of p53. Oncogene, 9, 3397-406.
82. Steinman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A. and el-Houseini, M. E. (1994). Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene, 9, 3389-96.
83. Scale, J. R. C., Varma, S., Swirsky, D., Pandolfi, P. P., Goldman, J. M. and Cross, N. C. P. (1996). Quantification of PML-RARα transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia specific mRNA by alpha interferon. Br. J. Haematol., 95, 95-101.
84. Peruzzi, D., DeBlasio, T., Warrell, R. P. J. and Pandolfi, P. P. (1996). Highly sensitive RT-PCR assay for detection of minimal residual disease in acute promyelocytic leukemia. Blood, 88, 366a.
85. Bouteille, M., Laval, M. and Dupuy-Coin, A. M. (1974). In The Cell Nucleus, H. Busch, (ed.) pp. 5-64, (Academic Press, New York).
86. Ascoli, C. and Maul, G. J. (1991). Identification of a novel nuclear domain. J. Cell. Biol., 112, 785-795.
87. Koken, M. H. M., Puvion-Dutilleul, F., Guillemin, M. C., Viron, A., Linares-Cruz, G., Stuurman, N., de Jong, L., Szostecki, C., Calvo, F., Chomienne, C., Degos, L., Puvion, E. and de Thé, H. (1994). The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J., 13, 1073-1083.
88. Dyck, J., Maul, G. G., Miller, W. H., Jr., Chen, J. D., Kakizuka, A. and Evans, R. M. (1994). A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell, 76, 333-343.
89. Weis, K., Rambaud, S., Lavau, C., Jansen, J., Carvalho, T., Carmo-Fonseca, M., Lamond, A. and Dejean, A. (1994). Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell, 76, 345-56.
90. Kastner, P., Perez, A., Lutz, Y., Rochette-Egly, C., Gaub, M. P., Durand, B., Lanotte, M., Berger, R. and Chambon, P. (1992). Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J, 11, 629-642.
91. Raelson, J. V., Nervi, C., Rosenauer, A., Benedetti, L., Monczak, Y., Pearson, M., Pelicci, P. G. and Miller, W. H., Jr. (1996). The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood, 88, 2826-32.
92. Yoshida, H., Kitamura, K., Tanaka, K., Omura, S., Miyazaki, T., Hachiya, T., Ohno, R. and Naoe, T. (1996). Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res, 56, 2945-8.
93. Lanotte, M., Martin-Thouvenin, V., Najman, S., Ballerini, P., Valensi, F. and Berger, R. (1991). NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood, 77, 1080-1086.
94. Gianni, M., Zanotta, S., Terao, M., Rambaldi, A. and Garattini, E. (1996). Interferons induce normal and aberrant retinoic-acid receptors type alpha in acute promyelocytic leukemia cells: potentiation of the induction of retinoid-dependent differentiation markers. Int. J. Cancer, 68, 75-83.
95. Fenaux, P., Chomienne, C. and Degos, L. (1997). Acute promyelocytic leukemia: biology and treatment. Semin. Oncol., 24, 92-102.
96. Lazzarino, M., Regazzi, M. B. and Corso, A. (1996). Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia. Leuk. Lymphoma, 23, 539-43.
97. Duprez, E., Ruchaud, S., Houge, G., Martin-Thouvenin, V., Valensi, F., Kastner, P., Berger, R. and Lanotte, M. (1992). A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features. Leukemia, 6, 1281-7.
98. Dermime, S., Grignani, F., Clerici, M., Nervi, C., Sozzi, G., Talamo, G. P., Marchesi, E., Formelli, F., Parmiani, G., Pelicci, P. G., et al. (1993). Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pm1/RAR alpha protein. Blood, 82, 1573-7.
99. Rosenauer, A., Raelson, J. V., Nervi, C., Eydoux, P., DeBlasio, A. and Miller, W. H., Jr. (1996). Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Stood, 88, 2671-82.
100. Kizaki, M., Matsushita, H., Takayama, N., Muto, A., Ueno, H., Awaya, N., Kawai, Y., Asou, H., Kamada, N. and Ikeda, Y. (1996). Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood, 88, 1824-33.
101. Shao, W., Benedetti, L., Lamph, W. W., Nervi, C. and Miller, W. H., Jr. (1997). A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood, 89, 4282-9.
102. Koller, E., Krieger, O., Kasparu, H. and Lutz, D. (1991). Restoration of all-trans retinoic acid sensitivity by interferon in acute promyelocytic leukaemia [letter] [see comments]. Lancet, 338, 1154-5.
103. Lazzarino, M., Corso, A., Regazzi, M. B., Iacona, I. and Bemasconi, C. (1995). Modulation of all-trans retinoid acid pharmacokinetics in acute promyelocytic leukaemia by prolonged interferon-alpha therapy. Br. J. Haematol., 90, 928-30.
104. Mu, Z.-M., Chin, K.-V., Liu, J.-H., Lozano, G. and Chang, K.-S. (1994). PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol. Cell. Biol., 14, 6858-6867.
105. Koken, M. H. M., Linares-Cruz, G., Quignon, F., Viron, A., Chelbi-Alix, M. K., Sobczak-Thepot, J., Juhlin, L., Degos, L., Calvo, F. and de Thé, H. (1995). The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene, 10, 1315-1324.
106. Zheng, A., Savolainen, E. R. and Koistinen, P. (1996). All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia. Leuk. Res., 20, 243-8.
107. Ferrero, D., Carlesso, N., Bresso, P., Roux, V., Pregno, P., Gallo, E. and Pileri, A. (1997). Suppression of in vitro maintenance of non-promyelocytic myeloid leukemia clonogenic cells by all-trans retinoic acid: modulating effects of dihydroxylated vitamin D3, alpha interferon and 'stem cell factor'. Leuk. Res., 21, 51-8.
108. Mahon, F. X., Chahine, H., Barbot, C., Pigeonnier, V., Jazwiec, B., Reiffers, J. and Ripoche, J. (1997). All-trans retinoic acid potentiates the inhibitory effects of interferon alpha on chronic myeloid leukemia progenitors in vitro. Leukemia, 11, 667-73.
109. Wadler, S., Schwartz, E. L., Haynes, H., Rameau, R., Quish, A., Mandeli, J., Gallagher, R., Hallam, S., Fields, A., Goldberg, G., McGill, F., Jennings, S., Wallach, R. C. and Runowicz, C. D. (1997). All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group. Cancer, 79, 1574-80.
110. Bonnefoix, T., Gressin, R., Jacrot, M., Perron, P., Swiercz, P., Chaffanjon, P. and Sotto, J. J. (1997). Growth modulation of freshly isolated non-Hodgkin's B-lymphoma cells induced by various cytokines and all-trans-retinoic-acid. Leuk. Lymphoma, 25, 169-78.
111. Massad, L. S., Turyk, M. E., Bitterman, P. and Wilbanks, G. D. (1996). Interferon-alpha and all-trans-retinoic acid reversibly inhibit the in vitro proliferation of cell lines derived from cervical cancers. Gynecol. Oncol., 60, 428-34.
112. Widschwendter, M., Daxenbichler, G., Culig, Z., Michel, S., Zeimet, A. G., Mortl, M. G., Widschwendter, A. and Marth, C. (1997). Activity of retinoic acid receptor-gamma selectively binding retinoids alone and in combination with interferon-gamma in breast cancer cell lines. Int. J. Cancer, 71, 497-504.
113. Avvisati, G., Lo Coco, F., Diverio, D., Falda, M., Ferrara, F., Lazzarino, M., Russo, D., Petti, M. C. and Mandelli, F. (1996). AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood, 88, 1390-8.
114. He, L. Z., Tribioli, C., Rivi, R., Peruzzi, D., Pelicci, P. G., Soares, V., Cattoretti, G. and Pandolfi, P. P. (1997). Acute leukemia with promyelocytic features in PML/RARα transgenic mice. Proc. Natl. Acad. Sci. USA, 94, 5302-5307.
115. Brown, D., Kogan, S., Lagasse, E., Weissman, I., Alcalay, M., Pelicci, P. G., Atwater, S. and Bishop, J. M. (1997). A PMLRARa transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA, 94, 2551-2556.
116. Grisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G. and Ley, T. J. (1997). Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences. Blood, 89, 376-387.
117. Licht, J. D., Chomienne, C., Goy, A., Chen, A., Scott, A., Head, D. R., Michaux, J. L., Wu, Y., DeBlasio, A., Miller, W. H., Jr., Zelenetz, A. D., Willman, C. L., Chen, Z., Chen, S.-J., Zelent, A., Macintyre, E., Veil, A., Cortes, J., Kantarjian, H. and Waxman, S. (1995). Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood, 85, 1083-1094.
118. Zelent, A. (1994). Translocation of the RARα locus to the PML or PLZF gene in acute promyelocytic leukaemia. Br. J. Haematol., 86, 451-450.
119. Pandolfi, P. P. (1996). PML, PLZF and NPM in the pathogenesis of Acute Promyelocytic Leukemia. Haematologica, 81, 472-482.